fepblue semaglutide Oral Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Semaglutide for Weight Loss |

This article reflects the author's opinion and should not be regarded as a buy or sell recommendation or investment advice in any way

Patients who remain on lower doses may not experience the full appetite-suppressing effects needed for continued weight loss

Effects include reduced inflammatory markers in synovial fluid, preserved cartilage thickness on imaging, improved joint function scoring

More serious, though much rarer, risks have been identified, including a potential increased risk of pancreatitis and gallbladder problems

149 PPAR agonist Gemcabene prevented steatosis, inflammation, and hepatocyte ballooning, and inhibited fibrosis progression in a high-fat/high-calorie diet-fed murine model of NASH